Vor Biopharma’s (VOR) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Vor Biopharma (NASDAQ:VOR) in a report released on Friday morning,Weiss Ratings reports.

A number of other brokerages have also recently issued reports on VOR. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vor Biopharma in a report on Thursday, August 14th. Wall Street Zen downgraded Vor Biopharma to a “strong sell” rating in a research note on Saturday, June 28th. Zacks Research downgraded Vor Biopharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Wedbush restated an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Finally, Stifel Nicolaus raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vor Biopharma has a consensus rating of “Hold” and a consensus target price of $77.83.

Vor Biopharma Stock Performance

NASDAQ VOR opened at $27.19 on Friday. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The firm’s 50 day moving average price is $35.41. The company has a market capitalization of $186.25 million, a P/E ratio of -0.10 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Insider Activity

In other news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $30.05, for a total value of $349,060.80. Following the transaction, the insider owned 1,167,109 shares in the company, valued at $35,071,625.45. The trade was a 0.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. sold 25,027 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $28.11, for a total value of $703,508.97. Following the completion of the transaction, the director directly owned 1,401,226 shares of the company’s stock, valued at approximately $39,388,462.86. This represents a 1.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,810,144 shares of company stock valued at $45,516,074. Company insiders own 0.45% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds have recently made changes to their positions in the business. Ariose Capital Management Ltd purchased a new position in shares of Vor Biopharma in the 3rd quarter worth about $5,368,000. XTX Topco Ltd purchased a new position in Vor Biopharma in the second quarter valued at about $66,000. Goldman Sachs Group Inc. boosted its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Vor Biopharma during the 1st quarter valued at approximately $140,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Vor Biopharma during the 1st quarter worth approximately $100,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.